Kane Biotech Inc. (TSXV:KNE)

Kane Biotech Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.43	2.08	0.15	2.67	1.61
Revenue Growth (YoY)	-79.44%	1296.75%	-94.42%	65.96%	19.84%
Cost of Revenue	0.43	1.21	-	1.26	1.04
Gross Profit	-0	0.87	0.11	1.41	0.57
Selling, General & Admin	1.98	3.08	2.41	3.72	4.07
Research & Development	0.67	1.72	1.05	1.05	1.38
Total Operating Expenses	2.65	4.8	3.47	4.78	5.45
Operating Income	-2.65	-3.92	-3.36	-3.36	-4.88
Interest Income	-0.02	-0	-	0.92	0.54
Interest Expense	0.24	0.55	-	-	-
Other Non-Operating Income (Expense)	0.17	0.54	-	-0.21	0.35
Total Non-Operating Income (Expense)	0.39	1.08	-	0.71	0.89
Pretax Income	-2.26	-2.84	-3.36	-2.65	-3.99
Provision for Income Taxes	-0.11	-1.31	-	-	-
Net Income	-2.72	6.17	-5.27	-3.82	-4.85
Minority Interest in Earnings	-	0.07	-	0.07	-0.25
Earnings From Discontinued Operations	-	18.59	-0.71	-	-
Net Income to Common	-2.72	6.17	-5.27	-3.82	-4.85
Shares Outstanding (Basic)	162	134	127	121	113
Shares Outstanding (Diluted)	162	155	127	121	113
Shares Change (YoY)	4.40%	22.23%	5.32%	7.20%	3.67%
EPS (Basic)	-0.02	-0.02	-0.04	-0.03	-0.04
EPS (Diluted)	-0.02	-0.02	-0.04	-0.03	-0.04
Shares Outstanding	181.6	137.79	131.85	124.83	114.81
Free Cash Flow	-3.26	-4.14	-2.09	-3.05	-2.48
Free Cash Flow Per Share	-0.02	-0.03	-0.02	-0.03	-0.02
Gross Margin	-0.15%	41.91%	73.48%	52.96%	35.36%
Operating Margin	-620.25%	-188.53%	-2253.58%	-126.06%	-303.75%
Profit Margin	-636.00%	-151.91%	-2253.58%	-99.44%	-248.30%
FCF Margin	-761.99%	-198.77%	-1403.79%	-114.40%	-153.99%
EBITDA	-2.49	-3.7	-3.12	-3.11	-4.7
EBITDA Margin	-582.21%	-178.03%	-2093.43%	-116.41%	-292.06%
EBIT	-2.65	-3.92	-3.36	-3.36	-4.88
EBIT Margin	-620.25%	-188.53%	-2253.58%	-126.06%	-303.75%
Effective Tax Rate	4.78%	46.10%	0.00%	0.00%	0.00%

Updated Apr 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.